POLYPID LTD (PYPD) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:PYPD • IL0011326795

4.87 USD
+0.29 (+6.33%)
At close: Feb 2, 2026
5.14 USD
+0.27 (+5.54%)
After Hours: 2/2/2026, 8:00:01 PM
Fundamental Rating

2

Overall PYPD gets a fundamental rating of 2 out of 10. We evaluated PYPD against 191 industry peers in the Pharmaceuticals industry. While PYPD seems to be doing ok healthwise, there are quite some concerns on its profitability. PYPD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year PYPD has reported negative net income.
  • In the past 5 years PYPD always reported negative net income.
  • PYPD had a negative operating cash flow in each of the past 5 years.
PYPD Yearly Net Income VS EBIT VS OCF VS FCFPYPD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M

1.2 Ratios

  • The Return On Assets of PYPD (-127.48%) is worse than 82.72% of its industry peers.
  • PYPD has a worse Return On Equity (-222.69%) than 74.87% of its industry peers.
Industry RankSector Rank
ROA -127.48%
ROE -222.69%
ROIC N/A
ROA(3y)-141.15%
ROA(5y)-114.23%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PYPD Yearly ROA, ROE, ROICPYPD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

  • PYPD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PYPD Yearly Profit, Operating, Gross MarginsPYPD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

  • PYPD has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, PYPD has more shares outstanding
  • PYPD has a better debt/assets ratio than last year.
PYPD Yearly Shares OutstandingPYPD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
PYPD Yearly Total Debt VS Total AssetsPYPD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -14.53, we must say that PYPD is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of PYPD (-14.53) is worse than 78.01% of its industry peers.
  • PYPD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -14.53
ROIC/WACCN/A
WACCN/A
PYPD Yearly LT Debt VS Equity VS FCFPYPD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

  • PYPD has a Current Ratio of 2.57. This indicates that PYPD is financially healthy and has no problem in meeting its short term obligations.
  • PYPD has a Current ratio (2.57) which is in line with its industry peers.
  • PYPD has a Quick Ratio of 2.57. This indicates that PYPD is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 2.57, PYPD perfoms like the industry average, outperforming 52.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.57
Quick Ratio 2.57
PYPD Yearly Current Assets VS Current LiabilitesPYPD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 62.36% over the past year.
EPS 1Y (TTM)62.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 19.17% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y56.72%
EPS Next 2Y31.82%
EPS Next 3Y21.77%
EPS Next 5Y19.17%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PYPD Yearly Revenue VS EstimatesPYPD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
PYPD Yearly EPS VS EstimatesPYPD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PYPD. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PYPD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PYPD Price Earnings VS Forward Price EarningsPYPD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PYPD Per share dataPYPD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

  • PYPD's earnings are expected to grow with 21.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.82%
EPS Next 3Y21.77%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for PYPD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

POLYPID LTD

NASDAQ:PYPD (2/2/2026, 8:00:01 PM)

After market: 5.14 +0.27 (+5.54%)

4.87

+0.29 (+6.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12
Earnings (Next)02-11
Inst Owners33.79%
Inst Owner Change-95.08%
Ins Owners5.52%
Ins Owner ChangeN/A
Market Cap80.99M
Revenue(TTM)N/A
Net Income(TTM)-34.22M
Analysts82
Price Target12.5 (156.67%)
Short Float %0.51%
Short Ratio0.85
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.55%
Min EPS beat(2)-39.67%
Max EPS beat(2)30.58%
EPS beat(4)2
Avg EPS beat(4)-4.29%
Min EPS beat(4)-39.67%
Max EPS beat(4)30.58%
EPS beat(8)4
Avg EPS beat(8)-4.32%
EPS beat(12)7
Avg EPS beat(12)5.15%
EPS beat(16)10
Avg EPS beat(16)3.6%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2%
EPS NQ rev (1m)0%
EPS NQ rev (3m)34.43%
EPS NY rev (1m)0%
EPS NY rev (3m)14.53%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.27
P/tB 5.27
EV/EBITDA N/A
EPS(TTM)-2.94
EYN/A
EPS(NY)-1.29
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.92
TBVpS0.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -127.48%
ROE -222.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-141.15%
ROA(5y)-114.23%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.57
Quick Ratio 2.57
Altman-Z -14.53
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)39.45%
Cap/Depr(5y)86.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.67%
EPS Next Y56.72%
EPS Next 2Y31.82%
EPS Next 3Y21.77%
EPS Next 5Y19.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-26.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.41%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-26.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-27.43%
OCF growth 3YN/A
OCF growth 5YN/A

POLYPID LTD / PYPD FAQ

What is the fundamental rating for PYPD stock?

ChartMill assigns a fundamental rating of 2 / 10 to PYPD.


Can you provide the valuation status for POLYPID LTD?

ChartMill assigns a valuation rating of 1 / 10 to POLYPID LTD (PYPD). This can be considered as Overvalued.


Can you provide the profitability details for POLYPID LTD?

POLYPID LTD (PYPD) has a profitability rating of 0 / 10.


What is the expected EPS growth for POLYPID LTD (PYPD) stock?

The Earnings per Share (EPS) of POLYPID LTD (PYPD) is expected to grow by 56.72% in the next year.